Enbrel® (Etanercept) is a medication that is manufactured by Pfizer and Amgen. It has been mostly prescribed to treat plaque psoriasis and various types of arthritis such as rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
The FDA approved Enbrel® in 1998 to treat rheumatoid arthritis in both adult and juvenile patients; however, a numerous amount of patients reported serious infections, including sepsis, Hepatitis B and tuberculosis. Other serious side effects caused by Enbrel® are systemic lupus erythematosus which show symptoms of red puffy face, skin lesions, skin eruptions, infections, and eczema, fever, body rash, fatigue, and joint pains. Enbrel® has been linked to incurable lymph cancer in arthritis patients. Enbrel® pediatric patients have developed blood disorders, melanoma, lymphomas, leukemia, heart failure and certain organ cancers due to the side effects of Enbrel and two other drugs of the same class, Remicade® and Humira®.